Chinese Journal of Pharmacovigilance ›› 2017, Vol. 14 ›› Issue (4): 222-225.
Previous Articles Next Articles
HAO Li-pan, WANG Shu-ling
Received:
2017-07-05
Revised:
2017-07-05
Online:
2017-04-20
Published:
2017-07-05
CLC Number:
HAO Li-pan, WANG Shu-ling*. Research on the Management of Waste Drugs Based on Extended Producer Responsibility[J]. Chinese Journal of Pharmacovigilance, 2017, 14(4): 222-225.
[1] 环境保护部.国家危险废物名录[EB/OL].(2016-06-14)[2017-03-29]. http://www.zhb.gov.cn/gkml/hbb/bl/201606/t20160621_354852.htm. [2] GB/T 18354-2006, 中华人民共和国国家标准:物流术语[S]. [3] 王君平.目前我国每个家庭过期药品达200多粒:过期药都去哪了[N]. 人民日报,2014-04-09 (02). [4] 侯崇智、杨文娟. 我国超八成家庭没有清理过期药品[N]. 人民网, 2014-03-20 (13). [5] 陈世吉,蔡金炼, 柯福志. 一起因销毁过期药品污染环境而引起中毒的事故调查[J]. 海峡预防医学杂志,2005, 11(3):42-42. [6] 肖纯,左雪莲. 我国药品逆向物流发展的障碍及对策分析[J]. 物流技术, 2006, (10): 7-9. [7] 罗凯,徐逸桥. 美国药品供应链的创新[J]. 物流, 2008, (5): 14-15. [8] 广药白云山.中国家庭过期药品回收白皮书(2004-2014年)[Z]. 广州:广药集团白云山, 2015. [9] 雷婷,叶桦. 家庭废弃药品的潜在危害和回收成本分析[J]. 中国药事, 2008, 22(7): 445-446. [10] 黎秋玲,庞倩影. 家用剩余药品怎样处理 过期药品有害勿随意扔掉[N]. 北京晚报, 2014-03-19 (4). [11] Thomas, Lindhqvist, Reid Lisfest. Can we take the concept of individual producer responsibility from theory to practice?[J]. Journal of Industrical Ecology, 2010, 7(2):3-6. [12] 魏洁. 企业逆向物流制度与模式[M]. 北京:人民邮电出版社, 2009: 12-13. [13] 国务院办公厅.国务院办公厅关于印发生产者责任延伸制度推行方案的通知[EB/OL].(2017-01-03)[2017-03-29].http://www.gov.cn/zhengce/content/2017-01/03/content_5156043.htm. [14] 刘婷. 基于三方进化博弈的药品回收逆向物流分析[J]. 物流科技, 2014, 37(2): 115-120 [15] 张亚轩. 基于逆向物流的过期药品回收演化博弈研究[D].2015: 56-57. |
[1] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
[2] | MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172. |
[3] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
[4] | GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5. |
[5] | MA Li’na, HU Xiaozhen, ZHENG Changhui, SUN Ying, ZHAO Xu, CAO Junling, XIAO Xiaohe. Visual analysis of knowledge map of toxic Chinese medicine Changshan toxicity-effect transformation based the thought of “yin du wei neng” [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 25-32. |
[6] | LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101. |
[7] | TIAN Chunhua, WU Guizhi. Implementation of periodic benefit risk evaluation reports in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384. |
[8] | ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang. Post-marketing active monitoring of medical devices under vigilance [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390. |
[9] | PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao. Establishment of patient reporting scheme in the UK and its implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263. |
[10] | WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan. Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089. |
[11] | JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang. Evaluation index system of MAH pharmacovigilance work [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094. |
[12] | LIU Hongliang, WANG Qing, HOU Yongfang. Design and implementation of polypharmacy risk data management platform for common diseases of the elderly based on real world data [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1095-1098. |
[13] | XIA Xudong, LI Meixia, SUN Yang, YANG Shengya. Processes of remote inspection of pharmacovigilance for marketing authorization holders [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970. |
[14] | LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977. |
[15] | SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||